A long lead in a niche industry ripe for disruption could make this stock a top performer. For longer than most folks reading this have been alive, Warren Buffett has been getting rich by acting greedy while the rest of the market is fearful. According to one popular indicator, it's nearly time to start acting greedy. A key measure of stock market fear, the CBOE S&P 500 Volatility Index, or VIX, spiked above 60 points on the morning of Monday, Aug. 5. That's higher than it's been since the COVID-19 pandemic ...

TransMedics (TMDX) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, TMDX crossed above the 20-day moving average, suggesting a short-term bullish trend. A well-liked tool among traders, the 20-day simple moving average offers a look back at a stock's price over a 20-day period. This is very beneficial to short-term traders, as it smooths out short-term price trends and gives more trend reversal signals than longer-term moving averages ...

CatLane Back in October 2023, I was adding aggressively to my TransMedics Group, Inc. (NASDAQ:TMDX) position when the stock dipped into the $30s. I was also adding aggressively before Q1 2024 earnings. Back in March/April, as I was trimming 90-95% of my Celsius Holdings, Inc. (CELH) and Super Micro Computer, Inc. (SMCI) positions, I was using that cash to add to many of my holdings, including TMDX. It became my largest position, and it's been that way for approximately three months. Even though TMDX is up m ...

TransMedics (TMDX) could be a solid choice for investors given the company's remarkably improving earnings outlook. While the stock has been a strong performer lately, this trend might continue since analysts are still raising their earnings estimates for the company. Analysts' growing optimism on the earnings prospects of this medical technology company is driving estimates higher, which should get reflected in its stock price. After all, empirical research shows a strong correlation between trends in earn ...

sturti TransMedics Group (NASDAQ:TMDX) had a remarkable second quarter, with another beat & raise. It's tough to say what the market thinks of the results, as the stock initially popped double-digits in the after-hours, but then came back down to being up just ~6% as the broad market sell-off intensified. There are three key questions I'm monitoring as TransMedics continues to execute its long-term plan. Let's dive in. Introduction To TransMedics I wrote my first article covering TransMedics back in March, ...

For the quarter ended June 2024, TransMedics (TMDX) reported revenue of $114.31 million, up 117.9% over the same period last year. EPS came in at $0.35, compared to -$0.03 in the year-ago quarter. The reported revenue compares to the Zacks Consensus Estimate of $98.63 million, representing a surprise of +15.89%. The company delivered an EPS surprise of +66.67%, with the consensus EPS estimate being $0.21. While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall S ...

Financial Performance - Total revenue for the three and six months ended June 30, 2024, was $114.3 million and $211.2 million, respectively, with net income of $12.2 million and $24.4 million for the same periods[56] - The company generated total revenue of $241.6 million and incurred a net loss of $25.0 million for the year ended December 31, 2023[56] - As of June 30, 2024, the company had an accumulated deficit of $479.3 million[56] - Total revenue increased by $61.8 million to $114.3 million in Q2 2024 compared to $52.5 million in Q2 2023, driven by higher net product and service revenue[67] - Net product revenue grew by $29.3 million to $71.7 million in Q2 2024, while service revenue surged by $32.6 million to $42.6 million[67] - Gross profit increased by $32.5 million to $69.3 million in Q2 2024, with overall gross margin at 61%, down from 70% in Q2 2023 due to higher service revenue mix[69] - Net income improved significantly to $12.2 million in Q2 2024 from a net loss of $1.0 million in Q2 2023[67] - Total revenue for the first six months of 2024 reached $211.2 million, a $117.1 million increase compared to the same period in 2023[74] - Gross profit for the first six months of 2024 was $129.2 million, up $63.7 million from the same period in 2023[74] - Net income for the first six months of 2024 was $24.4 million, a $28.0 million improvement from a net loss of $3.6 million in the same period of 2023[74] - Gross profit increased by $63.7 million in the six months ended June 30, 2024, compared to the same period in 2023, with overall gross margin at 61% in 2024, down from 70% in 2023 due to increased service revenue[77] Revenue Growth and Expectations - The company expects revenue growth from the expansion of the NOP in the United States and anticipated growth in non-U.S. sales if healthcare systems reimburse for OCS usage[60] - Gross margin is expected to decrease in 2024 as service revenue increases as a proportion of overall revenue, but long-term gross margin is expected to improve due to economies of scale and manufacturing efficiency[61] - The company anticipates increased service revenue from logistics services following the acquisition of Summit and the addition of a logistics team[59] - OCS transplant revenue in the US grew by $59.5 million to $108.5 million in Q2 2024, driven by higher sales of OCS Liver, Heart, and Lung disposable sets and increased NOP utilization[68] - OCS transplant-related revenue in the United States reached $200.3 million for the six months ended June 30, 2024, a $113.9 million increase compared to the same period in 2023, driven by higher sales volumes of OCS Liver, Heart, and Lung disposable sets and increased usage of the NOP[76] - Total OCS transplant revenue for all other countries was $8.8 million for the six months ended June 30, 2024, compared to $7.6 million in the same period in 2023[76] Research and Development - Research, development, and clinical trials expenses are expected to increase over the long term due to ongoing product development and regulatory approval efforts[63] - Research and development expenses increased by $5.6 million to $13.9 million in Q2 2024, primarily due to next-generation OCS program development[70] - Research, development, and clinical trials expenses increased by $11.1 million to $25.2 million in the six months ended June 30, 2024, driven by personnel-related costs and laboratory supplies for next-generation OCS development[80] Operating Expenses - Selling, general, and administrative expenses rose by $13.5 million to $42.9 million in Q2 2024, mainly due to personnel and facility-related costs[71] - Selling, general, and administrative expenses increased by $24.7 million to $79.1 million in the six months ended June 30, 2024, primarily due to personnel-related costs and facility-related expenses[81] Financing and Debt - The company issued $460.0 million in aggregate principal amount of 1.50% convertible senior notes due 2028 in May 2023[65] - Interest expense increased to $7.2 million in the six months ended June 30, 2024, compared to $3.6 million in the same period in 2023, due to interest on the $460.0 million Notes issued in May 2023[82] - The company issued $460.0 million in Convertible Senior Notes with an initial conversion price of $94.00 per share, representing a 32.5% premium over the May 8, 2023 closing price[89] - Net proceeds from the Notes issuance were approximately $393.3 million after deducting capped call transaction costs of $52.1 million and other issuance costs of $14.6 million[89] - The Notes bear interest at 1.50% per year and have an initial conversion rate of 10.6388 shares per $1,000 principal amount[89] - The company borrowed $60.0 million under the CIBC Credit Agreement, with interest rates tied to SOFR or prime rate plus a margin[90] - The company must maintain a minimum liquidity amount of the greater of consolidated adjusted EBITDA loss or $10.0 million under the CIBC Credit Agreement[91] Cash Flow and Liquidity - Cash and cash equivalents stood at $362.8 million as of June 30, 2024, with net cash provided by operating activities of $22.3 million for the six months ended June 30, 2024[84][85] - Net cash used in investing activities was $67.9 million for the six months ended June 30, 2024, primarily due to $53.6 million spent on transplant aircraft[87] - Net cash provided by financing activities was $13.8 million for the six months ended June 30, 2024, mainly from the issuance of common stock upon exercise of stock options[88] - The company believes its existing cash will fund operations, capital expenditures, and debt service for at least 12 months[93] - The company may need to raise additional funding, which might not be available on favorable terms[94] - There have been no material changes to the company's cash requirements or critical accounting policies[95][96] Regulatory and Market Expansion - The company received CE Mark recertification for OCS Heart, OCS Lung, and OCS Liver systems in 2022 and 2023, enabling sales in the EU[59] Operational Investments - The company acquired two fixed-wing aircraft for a total purchase price of approximately $28.0 million in July 2024, to be utilized for aviation transportation services as part of the NOP[55] - The company expects increased costs and expenses as it expands commercial sales, manufacturing, and R&D efforts for its OCS products[92] Risk Factors - The company is exposed to interest rate and foreign currency exchange risks but has not experienced material changes in these risks[98]

This medical technology disruptor continues to impress investors. Shares of TransMedics Group (TMDX 10.74%) were soaring 11.1% higher as of 11:22 a.m. ET on Thursday. The big gain came after the medical technology company announced its second-quarter results following the market close on Wednesday. TransMedics reported Q2 revenue of $114.3 million, up 118% year over year. It generated net income of $12.2 million, or $0.35 per diluted share. In the same quarter of 2023, TransMedics posted a net loss of $1 mi ...

TransMedics Group's robust second quarter was fueled by its Organ Care System and the National OCS Program segments. Key Points Revenue of $114.3 million, a 118% increase year over year. Full-year revenue guidance increased to $425 million to $445 million. Net income of $12.2 million, improving from a net loss of $1 million in the prior year. TransMedics Group (TMDX 2.77%), a pioneer in organ transplantation technology, released second-quarter earnings on Wednesday that reported an impressive 118% year-over ...

TransMedics Group, Inc. (NASDAQ:TMDX) Q2 2024 Earnings Conference Call July 31, 2024 4:30 PM ET Company Participants Laine Morgan - Gilmartin Group, Investor Relations Waleed Hassanein - President & Chief Executive Officer Stephen Gordon - Chief Financial Officer Conference Call Participants Allen Gong - JPMorgan William Plovanic - Canaccord Joshua Jennings - TD Cowen Matthew O'Brien - Piper Sandler Patrick Wood - Morgan Stanley Suraj Kalia - Oppenheimer & Company George Sellers - Stephens Inc. Operator Goo ...